241 related articles for article (PubMed ID: 28056301)
1. [Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].
Wang Y; Da JP; Wang XH; Song AP; Chen H; Zhang HL; Chen S; Wang DW
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):854-858. PubMed ID: 28056301
[No Abstract] [Full Text] [Related]
2. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
Takada K; Toyokawa G; Tagawa T; Kohashi K; Shimokawa M; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
Lung Cancer; 2018 Feb; 116():1-6. PubMed ID: 29413045
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
[TBL] [Abstract][Full Text] [Related]
6. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
7. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
[TBL] [Abstract][Full Text] [Related]
8. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
[No Abstract] [Full Text] [Related]
9. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
11. Significance of programmed death-ligand 1 expression in resected lung cancer and its relationship with EGFR mutation.
Osoegawa A; Abe M; Takumi Y; Hashimoto T; Karashima T; Miyawaki M; Sugio K
Thorac Cancer; 2023 Aug; 14(24):2467-2472. PubMed ID: 37455369
[TBL] [Abstract][Full Text] [Related]
12. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Nakano Y; Makino T; Otsuka H; Sano G; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
Oncol Rep; 2018 Jul; 40(1):331-338. PubMed ID: 29767258
[TBL] [Abstract][Full Text] [Related]
15. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
[TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
20. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
Cho JH; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
J Cancer Res Clin Oncol; 2019 May; 145(5):1341-1349. PubMed ID: 30900155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]